Metformin Therapy in Non-diabetic AAA Patients

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 170 participants.

Also called NCT03507413

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 170 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03507413
Other papers using this trial's data
  • MetAAA Trial Patients Receiving Metformin Therapy Show Limited Improvement in Quality of Life Compared to AAA Patients with Placebo Intake-A Double-Blind, Randomized, and Placebo-Controlled Trial Medical sciences (Basel, Switzerland), 2025-11-15 DOI, PubMed 41283274, PMC12641964 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Austria (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03507413. Randomized; quadruple masking; primary purpose treatment. Start 2018-09-26 (actual); primary completion 2024-05-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin Therapy in Non-diabetic AAA Patients
Acronym
MetAAA
Condition
Abdominal Aortic Aneurysm
Intervention (Drug)
Metformin Glucophage 500mg (IR) tablets M90
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Medical University of Vienna (class: other)
Collaborator
Merck Serono GmbH, Germany (class: industry)

Record details

Record id
cardio:ct-nct03507413
Content hash
7b63c0fe0821b9f5315989a08c8960bce53126aafdc2769e5ce2f1a62e25ab1f